On May 9, 2019 the Food and Drug Administration issued a “Recommendations for Reducing the Risk of Transfusion-Transmitted Babesiosis” guidance document with a maximum 12 month implementation timeline. Per the FDA guidance document recommendations, CTS is developing a specific implementation plan for mandatory Babesia testing well before the May 8, 2020 deadline.
Check out the Communication page for the complete details by clicking the link: Communications
The CTS Medical Advisory Board recently agreed upon a revision to our standard testing algorithm thi...
In July, all 5 CTS laboratories will convert from the current Grifols Ultrio Plus NAT triplex assay ...
We sincerely hope to see you at this year’s AABB Annual Meeting in San Antonio, TX on October ...
Just a reminder that the revised client forms implement today! Don't forget to toss your o...
At CTS, we understand the impact converting to the Ortho viral marker platform has on your operation...
After a thorough and comprehensive review of proposals received from suppliers of viral marker testi...